
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : University of Health Sciences Lahore
Deal Size : Inapplicable
Deal Type : Inapplicable
Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus
Details : Empagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 14, 2022
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : University of Health Sciences Lahore
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Rawalpindi Medical College
Deal Size : Inapplicable
Deal Type : Inapplicable
Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities
Details : Vortioxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : Vortioxetine Hydrobromide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Rawalpindi Medical College
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sunnyd Stat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Rawalpindi Medical College
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparative Pharmacokinetics of Two Different Oral Delivery Systems of Cholecalciferol
Details : Sunnyd Stat is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Vitamin D Deficiency.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 03, 2021
Lead Product(s) : Sunnyd Stat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Rawalpindi Medical College
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apixaban
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Rawalpindi Medical College
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apixaban is a HPAPI drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
October 22, 2021
Lead Product(s) : Apixaban
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Rawalpindi Medical College
Deal Size : Inapplicable
Deal Type : Inapplicable
